Table 5.
Summary of the reports of concomitant extra-pancreatic cancers in patients with IPMN
| Author (yr) | Number of IPMN patients | Extra-pancreatic cancers with IPMN patients | Age (mean ± SD) | Male:female | Follow-up period (mo) |
| Zhong (1996) | 21 | 5 | NA | NA | NA |
| Sugiyama (1999) | 42 | 15 | NA | NA | NA |
| Adsay (2002) | 28 | 8 | NA | NA | NA |
| Osanai (2003) | 148 | 35 | 70.9 | 31:4 | NA |
| Kamisawa (2005) | 79 | 37 | NA | NA | NA |
| Eguchi (2006) | 69 | 32 | NA | NA | NA |
| Choi (2006) | 61 | 18 | 64.2 ± 8.4 | 13:5 | 65.8 ± 8.5 |
| Yoon (2008) | 210 | 77 | 65.3 ± 9.0 | 47:30 | 24.7 |
| Ishida (2008) | 61 | 151 | 67.0 ± 7.0 | 12:3 | 50.9 |
| Present study | 145 | 422 | 68.3 ± 9.0 | 20:26 | 49.8 ± 42.4 |
| Total | 864 | 2843 |
1
In those 2 patients who had metachronous double extra-pancreatic malignancies;
2
In those 4 patients who had metachronous double extra-pancreatic malignancies;
3
In those 6 patients who had metachronous double extra-pancreatic malignancies. NA: Not available.